ALS Drug Trial Enrollment Complete
Enrollment is finished in a Phase 2b/3 study of ibudilast (MN-166) for Amyotrophic lateral sclerosis. The study will test if the drug can safely slow progression, with results expected by the end of 2026. If you can't join, expanded access and an open-label period may offer ongoing access to the therapy.
Research#Amyotrophic Lateral Sclerosis (ALS)#Motor Neurone Disease (MND)#MN-166#Clinical Trial